Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | IDO1 | P14902 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | PHGDH | O43175 | 1/20 | 0.55 |
| ▸ | HTR6 | P50406 | 2/20 | 0.54 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7164868 | 0.92 | MAPT (0.84) | MAPTL3MBTL1MAPK1IDO1TDP1 | |
| SCHEMBL132598 | 0.87 | MAPT (0.77) | MAPTL3MBTL1MAPK1IDO1TDP1 | |
| SCHEMBL102602 | 0.87 | MAPT (0.77) | MAPTL3MBTL1MAPK1TDP1LMNA | |
| SCHEMBL10353552 | 0.86 | MAPT (0.76) | MAPTL3MBTL1MAPK1IDO1TDP1 | |
| SCHEMBL95687 | 0.85 | MAPT (0.74) | MAPTL3MBTL1MAPK1IDO1TDP1 | |
| SCHEMBL13783550 | 0.84 | MAPT (0.73) | MAPTL3MBTL1MAPK1TDP1LMNA | |
| SCHEMBL10360050 | 0.84 | MAPT (0.73) | MAPTL3MBTL1MAPK1TDP1LMNA | |
| SCHEMBL9683242 | 0.84 | MAPT (0.84) | MAPTL3MBTL1TDP1LMNAALDH1A1 | |
| SCHEMBL9138464 | 0.84 | MAPT (0.73) | MAPTL3MBTL1MAPK1TDP1LMNA | |
| SCHEMBL31325569 | 0.84 | MAPT (0.73) | MAPTL3MBTL1MAPK1TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111704579-B | Benzimidazole compound synthesis method based on iron-catalyzed redox coupling reaction | 中国农业大学 | 2021-12-14 | — | — | CN | disclosed |
| CN-111704579-A | Benzimidazole compound synthesis method based on iron-catalyzed redox coupling reaction | 中国农业大学 | 2020-09-25 | — | — | CN | disclosed |
| WO-2019028308-A1 | BENZIMIDAZOLES AND AZA-BENZIMIDAZOLES, AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2019-02-07 | — | — | WO | disclosed |
| US-8975247-B2 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNION UNIVERSITY (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975247-B2 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNION UNIVERSITY (US) | 2015-03-10 | — | — | US | disclosed |
| US-20120276050-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-11-01 | — | — | US | disclosed |
| US-20120276050-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-11-01 | — | — | US | disclosed |
| US-20120058085-A1 | Deuterium Modified Benzimidazoles | CONCERT PHARMACEUTICALS, INC. | 2012-03-08 | — | — | US | disclosed |
| US-20120058085-A1 | Deuterium Modified Benzimidazoles | CONCERT PHARMACEUTICALS, INC. | 2012-03-08 | — | — | US | disclosed |
| US-20120058085-A1 | Deuterium Modified Benzimidazoles | CONCERT PHARMACEUTICALS, INC. | 2012-03-08 | — | — | US | disclosed |
| WO-2010132810-A1 | DEUTERIUM MODIFIED BENZIMIDAZOLES | CONCERT PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010107739-A2 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2010-09-23 | — | — | WO | disclosed |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-02-04 | — | — | US | disclosed |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-02-04 | — | — | US | disclosed |
| US-20070212267-A1 | Method and apparatus for performing micro-scale chemical reactions | TOTAL SYNTHESIS LTD. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-20070212267-A1 | Method and apparatus for performing micro-scale chemical reactions | TOTAL SYNTHESIS LTD. (CA) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058085-A1 | Deuterium Modified Benzimidazoles | POLRMT, EIF2AK2, DUT | MAPT 4232/4885L3MBTL1 2089/4885MAPK1 2041/4885 |
| US-20120276050-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NSUN3, RNGTT, NSUN2 | MAPT 4638/4885L3MBTL1 183/4885MAPK1 4422/4885 |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | EIF2AK2, NSUN3, NSUN2 | MAPT 4569/4885L3MBTL1 389/4885MAPK1 4363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.